Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT04369183 is registered in ClinicalTrials.gov with Istanbul University as lead sponsor.

NCT NCT04369183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04369183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rituximab in Adult Patients With Refractory or Relapsed Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Lead sponsor
Istanbul University
Phase
Observational
Overall status
Completed
Start date
September 1, 2019
Completion date
October 31, 2020
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis, minimal change disease